Retatrutide and Temperature-Related Side Effects
The available evidence does not specifically document chills or temperature changes as recognized side effects of retatrutide. The most comprehensive clinical data on retatrutide's adverse event profile consistently identifies gastrointestinal symptoms as the predominant side effects, with no mention of fever, chills, or temperature dysregulation 1, 2, 3, 4.
Evidence from Clinical Trials
Documented Adverse Events
- Gastrointestinal effects are the most frequently reported adverse events with retatrutide across all phase 2 trials, including nausea, diarrhea, and vomiting 1, 2, 3, 4.
- In the obesity trial substudy (N=189), adverse events were similar between retatrutide and placebo groups, with no deaths reported and gastrointestinal events being most common 1.
- A systematic review of 1,082 screened patients found gastrointestinal adverse effects were the most commonly reported, with no significant difference in overall adverse events between retatrutide and placebo groups (relative risk: 1.11, P = 0.24) 3, 4.
What Is NOT Reported
- None of the published phase 2 clinical trials or systematic reviews mention chills, rigors, fever, or temperature changes as adverse events associated with retatrutide 1, 2, 3, 4, 5.
- The FDA drug label reference provided contains no specific adverse event information 6.
Context: Distinguishing from Infusion Reactions
It is important to note that chills and temperature changes are well-documented side effects of certain other therapeutic agents, particularly:
- Monoclonal antibodies and immunotherapies: Chills are common with agents like daratumumab (40-50% incidence), ipilimumab, cetuximab, and brentuximab vedotin 7.
- IL-2 therapy: Fevers, chills, and rigors are expected side effects, typically occurring 1-2 hours after each dose 8.
However, retatrutide is a subcutaneous peptide agonist, not an infusion therapy, and does not share the immunogenic mechanisms that cause infusion reactions 9.
Clinical Implications
- If a patient on retatrutide develops chills or temperature changes, alternative etiologies should be investigated rather than attributing these symptoms to the medication itself.
- Consider infectious causes, concurrent medications, or other medical conditions as the source of these symptoms.
- The safety profile of retatrutide appears favorable with appropriate tolerability when gastrointestinal side effects are managed 2, 3, 4.